The RESPECT trial is notable for demonstrating that the Amplatzer PFO Occluder is more beneficial than medical therapy in preventing recurrent stroke.1
The findings also revealed a reduction in the risk of recurrent cryptogenic stroke with the use of the Amplatzer PFO Occluder:1
RELATIVE RISK REDUCTION FOR RECURRENT CRYPTOGENIC STROKE 62%
RELATIVE RISK REDUCTION FOR ANY RECURRENT ISCHEMIC STROKE 45%
The trial analysis reveals that the device reduced recurrent ischemic stroke by eliminating a conduit through which venous source emboli can travel to the brain.